Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
Morepen Labs successfully raised Rs. 200 Crore through QIP
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
Trazodone tablets are indicated for the treatment of major depressive disorder in adults
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
The sales of medicines and other items sold through Jan Aushadhi Kendras have increased from Rs. 7.29 crore in 2014 to Rs. 1,470 crore by July 2024
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Subscribe To Our Newsletter & Stay Updated
